As recently discussed in the Journal,[@bib0001] baricitinib was safe and improved the clinical conditions in 12 patients with mild-moderate Coronavirus Disease 2019 (COVID-19) pneumonia. It is known that severe symptoms of COVID-19 may develop after a median of 8-days from illness-onset, with a median time to Intensive Care Unit (ICU) admission of 5 days from the dyspnea occurrence.[@bib0002] Currently, no antiviral therapies or vaccines are available. An uncontrolled immune response[@bib0003] is observed and is likely involved in tissues injury.[@bib0004] Baricitinib is an anti-Janus kinase inhibitor-1 and −2, and has a dual action on COVID-19 therapy including the inhibition of cytokine release and SARS-CoV-2 endocytosis.[@bib0005] Based on this evidence, we conducted an observational, retrospective, longitudinal multicenter-study in consecutive-hospitalized patients with COVID-19 moderate pneumonia to evaluate the 2-week effectiveness and safety of baricitinib combined with antivirals (lopinavir/ritonavir) compared with the standard of care therapy which was hydroxychloroquine and lopinavir/ritonavir. Primary aim was to evaluate the mortality rate; secondary aims were to evaluate the rate of ICU transfer, hospital discharge, improvement of respiratory parameters, adverse events (AEs) occurrence. Moreover, associations between therapy and modification of respiratory parameters and C-Reactive Protein (CRP), interleukin-6 (IL-6), lymphocyte percentage were evaluated.

Clinical charts of patients with moderate COVID-19 pneumonia from 7 Italian hospitals (Hospital of Prato, Hospital of Pistoia, Hospital S.Maria Nuova, Florence, Hospital of Alessandria, Hospital of Fano, Hospital of Pesaro, Hospital of Ariano Irpino (Avellino) were reviewed.

Baricitinib-treated arm included consecutive-hospitalized patients,18 years-older, SARS-CoV-2 naso-pharingeal swab-positive, with a moderate pneumonia characterized by typical symptoms, radiological findings of pneumonia, SpO2 \>92% on room air,and PaO2/FiO2 100--300 mmHg, admitted between March 15th-May 5th, 2020. Baricitinib 4 mg/day was provided orally associated with lopinavir/ritonavir tablets 250 mg/bid for 2 weeks.

Control-arm included all consecutive-hospitalized patients from February 20th-March 15th, 2020 with moderate COVID-19 pneumonia, 18 years-older, treated with hydroxychloroquine (HCLR) and lopinavir/ritonavir. Exclusion criteria were: history of thrombophlebitis, latent tuberculosis infection,[@bib0006] ^,^ [@bib0007] HBV or HCV infection, current varicella zoster or bacterial infection, pregnancy, lactation, contraceptive pills intake, previous (last 5 years) or current malignancy, neutrophil count\<1.0 × 10^9^/L, lymphocyte count\<0.2 × 10^9^/L, platelets count\<50 × 10^9^/L, transaminases values 4-fold higher than the upper normal limit. Prophylactic anti-thrombotic therapy with low-weight molecular heparin wasadministered. Patients had supportive therapy (O~2~ supply, rehydration, diuretics, anti-hypertensive, antibiotics) if needed. Corticosteroids were not allowed. If patients were discharged earlier than 2 weeks, they were requested to continue the ongoing therapy until the scheduled 14-days.

Temperature, respiratory and pulse rate, arterial blood gas analysis, blood pressure, blood cell count, liver and kidney tests function were daily assessed. IL-6 serum levels of (RayBio^Ⓡ^ Human IL-6 ELISA Kit, RayBiotech Co.,USA) were tested at baseline, week 1 and 2. Since low lymphocyte percentage can predict a poor prognosis[@bib0006], patients were stratified at baseline as: lymphocytes \>20%, \>5% to \<20%, and \<5%.

Patients provided a written-informed consent. The off-label use of baricitinib was approved by the Hospital-Committee and Ethical-Committee of Toscana-Region (Code: BARIC-off; 17,261; approval date: May 5th 2020).

Mann-Whitney U test was used to compare quantitative variables; Wilcoxon test for paired data; Chi-squared or Fisher\'s exact test for categorical variables. A two-tailed p-value \<0.05 was considered significant.

At baseline, 113 patients were in the baricitinib-arm, and 78 in the control-arm ([Table 1](#tbl0001){ref-type="table"} ). The results indicate that the 2-week case fatality rate was significantly lower in the baricitinib-arm compared with controls \[0% (0/113) vs 6.4% (5/78) (p-value: 0.010; 95%CI 0.0000--0.4569)\] ([Table 2](#tbl0002){ref-type="table"} ). ICU admission was requested in 0.88% (1/113) vs 17.9% (14/78) patients in the baricitinib-arm compared to the control-arm (week 1, p-value: 0.019; 95%CI 0.0092--0.6818), (week 2, p-value: \<0.0001; 95%CI 0.0038--0.2624). Discharge rate was significantly higher in the baricitinib-arm at week 1 \[9.7% (11/113) vs 1.3% (1/78) (p-value: 0.039; 95%CI: 1.41--90.71)\], and at week 2 \[77.8% (88/113) vs 12.8% (10/78) (p:\<0.0001; 95%CI 10.79--51.74)\].Table 1Baseline demographic, clinical, and laboratory characteristics of COVID-19 patients treated with lopinavir/ritonavir and either baricitinib or with standard of care therapy.Table 1FeatureBaricitinib\
Combined with lopinavir/ritonavir treated arm [a](#tb1fn1){ref-type="table-fn"}Hydroxychloroquine\
Combined with lopinavir/ritonavir treated arm\
(standard of care-treated arm) [b](#tb1fn2){ref-type="table-fn"}P valuePatient number, No (%)113 (100)78 (100)Male/female, No (%)73/40 (64.6/35.4)46/32 (59/41)0.524Age years, median (IQR)68 (57--76)63 (55.5--69.5)0.602Interval from symptoms onset and therapy starting, days, No7 (5--10)6.5 (4--9)0.915Cough, No (%)75/113 (66.4)53/78 (67.9)0.943Dyspnea, No (%)84/113 (74.3)58/78 (74.4)0.869Sputum production, No (%)41/113 (36.2)29/78 (37.2)0.979Headache, No (%)56/113 (49.5)31/78 (39.7)0.234Diarrhea, No (%)26/113 (23)11/78 (14.1)0.179Ageusia/anosmia, No (%)44/113 (38.9)29/78 (37.1)0.925Hypertension, No (%)32/113 (28.3)21/78 (26.9)0.962Diabetes, No (%)18/113 (15.9)13/78 (16.6)0.949COPD, No (%)16/113 (14.1)14/78 (17.9)0.613CVD, No (%)10/113 (8.5)5/78 (6.4)0.732Fever °C, median (IQR)37.9 (36.7--38.3)37.8 (37.7--38.7)0.915Breath rate n/min, median (IQR),20 (17--22)21 (19--24)0.825SpO2 (%),median (IQR)95 (92--98)93 (92--97)0.234PaO2/FiO2, median (IQR)265.7 (202--330)267.5 (263.1--301)0.522Pulse rate, median (IQR)80 (70--90)85 (79--92)0.129SBP mm/hg, median (IQR)125 (112--135)115 (105--130)0.121DBP mm/hg, median (IQR)70 (65--80)65 (60--72)0.232WBC (x10^9^/l), median (IQR)6.5 (4.9--8.3)7.2 (5.8--8.6)0.708Neutrophils (x10^9^/l), median (IQR)4.7 (3.5--6.5)4.9 (4.4--6.9)0.911Lymphocytes (x10^9^/l), median (IQR)0.93 (0.7--1.2)0.88 (0.7--0.9)0.728Lymphocyte percentage\>20 N (%)39 (34.5)24 (30.8)0.701\>5-\<2070 (61.9)51 (65.4)0.740\<54 (3.6)3 (3.8)0.779Hemoglobin (g/l), median (IQR)118 (101--134)125 (108--133)0.426Platelets (x10^9^/l), median (IQR)213 (167--308)268 (156--392)0.234Alt (u/l), median (IQR)29 (19--49)34 (25--52)0.168Ast (u/l), median (IQR)34 (25--51)40 (34--47)0.628Creatinine (mg/dl), median (IQR)0.9 (0.7--1.1)1.00 (0.9--1.2)0.925Crp (mg/dl), median (IQR)8.2 (4.1--14.5)6.3 (2.8--13.6)0.129IL-6 (PG/ML), MEDIAN (IQR) [c](#tb1fn3){ref-type="table-fn"}29.4 (16--45)32.6 (25--61)0.225Procalcitonin (ng/ml), median (IQR)0.6 (0.3--1.2)0.9 (0.8--2.1)0.802Mews, median (IQR)1 (0--2)2 (1--3)0.225[^1][^2][^3][^4]Table 2Clinical, laboratory and respiratory parameters of COVID-19 patients after 1- or 2-week treatment in the baricitinib-treated group and in the standard-treated group: comparison within the same treatment group and between the 2 different treatment groups.Table 2Baricitinib\
combined with lopinavir/ritonavir treated arm\
113 patientsHydroxychloroquine\
combined with lopinavir/ritonavir treated arm\
(Standard of care-treated arm)\
78 patientsBaricitinib-based therapy arm vs\
standard of care therapy armClinical, laboratory, respiratory parametersBaselineWeek 1Week 2P value\
Baseline values vs\
Week 1 [a](#tb2fn1){ref-type="table-fn"} or\
vs Week 2 [b](#tb2fn2){ref-type="table-fn"} valuesBaselineWeek 1Week 2P value\
Baseline values vs\
Week 1 [a](#tb2fn1){ref-type="table-fn"} or\
vs Week 2 [b](#tb2fn2){ref-type="table-fn"} valuesP value\
Week 1 [a](#tb2fn1){ref-type="table-fn"}\
Week 2 [b](#tb2fn2){ref-type="table-fn"}Cough, No (%)75 (66.4)25 (22.1)4 (3.5)0.000 [a](#tb2fn1){ref-type="table-fn"}\
0.000 [b](#tb2fn2){ref-type="table-fn"}53 (67.9)39 (50)15 (19.2)0.034 [a](#tb2fn1){ref-type="table-fn"}\
0.000 [b](#tb2fn2){ref-type="table-fn"}0.000 [a](#tb2fn1){ref-type="table-fn"}\
0.014 [b](#tb2fn2){ref-type="table-fn"}Dyspnea, No (%)84 (74.3)20 (1.7)4 (3.5)0.000 [a](#tb2fn1){ref-type="table-fn"}\
0.000 [b](#tb2fn2){ref-type="table-fn"}58 (74.4)51 (65.3)39 (50)0.295 [a](#tb2fn1){ref-type="table-fn"}\
0.003 [b](#tb2fn2){ref-type="table-fn"}0.000 [a](#tb2fn1){ref-type="table-fn"}\
0.000 [b](#tb2fn2){ref-type="table-fn"}Sputum production, No (%)41 (36.2)15 (13.2)10 (8.8)0.000 [a](#tb2fn1){ref-type="table-fn"}\
0.000 [b](#tb2fn2){ref-type="table-fn"}29 (37.2)18 (23)12 (15.3)0.081[a](#tb2fn1){ref-type="table-fn"}\
0.004 [b](#tb2fn2){ref-type="table-fn"}0.117 [a](#tb2fn1){ref-type="table-fn"}\
0.246 [b](#tb2fn2){ref-type="table-fn"}Headache, No (%)56 (49.5)12 (10.6)2 (1.7)0.000 [a](#tb2fn1){ref-type="table-fn"}\
0.000 [b](#tb2fn2){ref-type="table-fn"}31 (39.7)24 (30.7)10 (12.8)0.315 [a](#tb2fn1){ref-type="table-fn"}\
0.002 [b](#tb2fn2){ref-type="table-fn"}0.000 [a](#tb2fn1){ref-type="table-fn"}\
0.005 [b](#tb2fn2){ref-type="table-fn"}Diarrhea, No (%)26 (23)2 (1.7)00.000 [a](#tb2fn1){ref-type="table-fn"}\
0.000 [b](#tb2fn2){ref-type="table-fn"}11 (14.1)1 (1.3)00.007 [a](#tb2fn1){ref-type="table-fn"}\
0.002 [b](#tb2fn2){ref-type="table-fn"}0.745 [a](#tb2fn1){ref-type="table-fn"}\
NA [b](#tb2fn2){ref-type="table-fn"}Ageusia/Anosmia, No (%)44 (38.9)32 (28.3)24 (21.2)0.121 [a](#tb2fn1){ref-type="table-fn"}\
0.006 [b](#tb2fn2){ref-type="table-fn"}29 (37.1)25 (32)19 (24.3)0.614 [a](#tb2fn1){ref-type="table-fn"}\
0.118 [b](#tb2fn2){ref-type="table-fn"}0.694 [a](#tb2fn1){ref-type="table-fn"}\
0.740 [b](#tb2fn2){ref-type="table-fn"}Fever °C, median (IQR)38\
(37.4--38.2)36.1\
(36--36.4)36\
(36--36.1)0.001 [a](#tb2fn1){ref-type="table-fn"}\
0.001 [b](#tb2fn2){ref-type="table-fn"}38\
(37.7--38.7)37.5\
(36.5--38.1)37\
(36.3--37.4)0.516 [a](#tb2fn1){ref-type="table-fn"}\
0.129 [b](#tb2fn2){ref-type="table-fn"}0.000 [a](#tb2fn1){ref-type="table-fn"}\
0.000 [b](#tb2fn2){ref-type="table-fn"}Breath, N/min, median (IQR)20 (17--22)\
18\
(15--20)16\
(14--18)0.003 [a](#tb2fn1){ref-type="table-fn"}\
0.002 [b](#tb2fn2){ref-type="table-fn"}21 (19--24)19\
(18--22)17\
(16--21.7)0.083 [a](#tb2fn1){ref-type="table-fn"}\
0.058 [b](#tb2fn2){ref-type="table-fn"}0.724 [a](#tb2fn1){ref-type="table-fn"}\
0.225 [b](#tb2fn2){ref-type="table-fn"}SpO2%, median (IQR)95 (92--98)96\
(95--98)97\
(96--98)0.191 [a](#tb2fn1){ref-type="table-fn"}\
0.0018 [b](#tb2fn2){ref-type="table-fn"}93 (92--97)93.8\
(91.8--94.7)93.6\
(86.7--94.3)0.678 [a](#tb2fn1){ref-type="table-fn"}\
0.715 [b](#tb2fn2){ref-type="table-fn"}0.000 [a](#tb2fn1){ref-type="table-fn"}\
0.000 [b](#tb2fn2){ref-type="table-fn"}PaO2/FiO2 value, median (IQR)265.7 (202--330)336.5\
(245.5--452)395\
(320--452.3)0.0016 [a](#tb2fn1){ref-type="table-fn"}\
0.0000 [b](#tb2fn2){ref-type="table-fn"}267.5 (263.1--301)278.2\
(258.3--302.4)293.5\
(244.2--315.1)0.514 [a](#tb2fn1){ref-type="table-fn"}\
0.376 [b](#tb2fn2){ref-type="table-fn"}0.001 [a](#tb2fn1){ref-type="table-fn"}\
0.000 [b](#tb2fn2){ref-type="table-fn"}Pulse rate, No/min. median (IQR)80 (70--90)76\
(68.5--81)74.5\
(68--80)0.433 [a](#tb2fn1){ref-type="table-fn"}\
0.177 [b](#tb2fn2){ref-type="table-fn"}85 (79--92)82.5\
(76.5--91)83\
(77--96.4)0.433 [a](#tb2fn1){ref-type="table-fn"}\
0.903 [b](#tb2fn2){ref-type="table-fn"}0.129 [a](#tb2fn1){ref-type="table-fn"}\
0.004 [b](#tb2fn2){ref-type="table-fn"}WBC, x10^9^/L, median (IQR)6.5 (4.9--8.3)7.0 (5.7--9.2)7.0 (5.8--8.6)0.481 [a](#tb2fn1){ref-type="table-fn"}\
0.225 [b](#tb2fn2){ref-type="table-fn"}7.2 (5.8--8.6)6.9\
(6.5--7.4)7.2\
(6.4--8.6)0.789 [a](#tb2fn1){ref-type="table-fn"}\
0.922 [b](#tb2fn2){ref-type="table-fn"}0.389 [a](#tb2fn1){ref-type="table-fn"}\
0.533 [b](#tb2fn2){ref-type="table-fn"}Neutrophils, x10^9^/L, median (IQR)4.7 (3.5--6.5)5 (3.3--7)4.4\
(3.2--6.9)0.720 [a](#tb2fn1){ref-type="table-fn"}\
0.876 [b](#tb2fn2){ref-type="table-fn"}4.9 (4.4--6.9)5.4\
(5.1--6.2)6.7 (6.3--7.3)0.054 [a](#tb2fn1){ref-type="table-fn"}\
0.002 [b](#tb2fn2){ref-type="table-fn"}0.136 [a](#tb2fn1){ref-type="table-fn"}\
0.068 [b](#tb2fn2){ref-type="table-fn"}Lymphocytes, x10^9^/L, median (IQR)0.93 (0.7--1.2)1.11 (0.8--1.9)1.3 (1--2.1)0.0023 [a](#tb2fn1){ref-type="table-fn"}\
0.0017 [b](#tb2fn2){ref-type="table-fn"}0.88 (0.7--0.9)0.86 (0.5--1)0.9 (0.69--1.0)0.524 [a](#tb2fn1){ref-type="table-fn"}\
0.836 [b](#tb2fn2){ref-type="table-fn"}0.023 \*\
0.004 †Lymphocytes, No (%)\>2039 (34.5)\
57 (50.4)\
78 (69.0)\
0.022 [a](#tb2fn1){ref-type="table-fn"}\
0.000 [b](#tb2fn2){ref-type="table-fn"}24 (30.8)32 (41.0)\
35 (44.9)0.243 [a](#tb2fn1){ref-type="table-fn"}\
0.099 [b](#tb2fn2){ref-type="table-fn"}0.256 [a](#tb2fn1){ref-type="table-fn"}\
0.001 [b](#tb2fn2){ref-type="table-fn"}\>5-\<20\
70 (61.9)\
49 (43.4)\
28 (24.8)\
0.008 [a](#tb2fn1){ref-type="table-fn"}\
0.000 [b](#tb2fn2){ref-type="table-fn"}51 (65.4)39 (50.0)35 (44.9)0.075 [a](#tb2fn1){ref-type="table-fn"}\
0.016 [b](#tb2fn2){ref-type="table-fn"}0.449 [a](#tb2fn1){ref-type="table-fn"}\
0.006 [b](#tb2fn2){ref-type="table-fn"}\<54 (3.6)7 (6.2)7 (6.2)0.536 [a](#tb2fn1){ref-type="table-fn"}\
0.536 [b](#tb2fn2){ref-type="table-fn"}3 (3.8)7 (9.0)8 (10.2)0.327 [a](#tb2fn1){ref-type="table-fn"}\
0.211 [b](#tb2fn2){ref-type="table-fn"}0.658 [a](#tb2fn1){ref-type="table-fn"}\
0.452 [b](#tb2fn2){ref-type="table-fn"}Hb, g/L, median (IQR)118 (101--134)120\
(106--112)125\
(118--131)0.234 [a](#tb2fn1){ref-type="table-fn"}\
0.129 [b](#tb2fn2){ref-type="table-fn"}125 (108--133)122\
(112--125.2)124\
(114--128)0.812 [a](#tb2fn1){ref-type="table-fn"}\
0.534 [b](#tb2fn2){ref-type="table-fn"}0.925 [a](#tb2fn1){ref-type="table-fn"}\
0.746 [b](#tb2fn2){ref-type="table-fn"}Platelets, Nox10^9^/L, median (IQR)213 (167--308)347\
(265--426)284\
(205--419)0.121 [a](#tb2fn1){ref-type="table-fn"}\
0.189 [b](#tb2fn2){ref-type="table-fn"}268 (156--392)328 (321--461)359\
(316--423)0.268 [a](#tb2fn1){ref-type="table-fn"}\
0.189 [b](#tb2fn2){ref-type="table-fn"}0.786 [a](#tb2fn1){ref-type="table-fn"}\
0.144 [b](#tb2fn2){ref-type="table-fn"}ALT, U/L, median (IQR)29 (19--49)45 (29--68)\
(43.2--57.2)45 (26.7--71\
(43--83.7)0.065 [a](#tb2fn1){ref-type="table-fn"}\
0.076 [b](#tb2fn2){ref-type="table-fn"}34 (25--52)57.5\
(38--69.4)54.8\
(39.5--54.5)0.049 [a](#tb2fn1){ref-type="table-fn"}\
0.057 [b](#tb2fn2){ref-type="table-fn"}0.533 [a](#tb2fn1){ref-type="table-fn"}\
0.144 [b](#tb2fn2){ref-type="table-fn"}AST, U/L, median (IQR)34 (25--51)36\
(25--49.2)30\
(23--43.5)0.965 [a](#tb2fn1){ref-type="table-fn"}\
0.764 [b](#tb2fn2){ref-type="table-fn"}40 (34--47)46.5\
(41.7--52.5)48.5\
(42--55.8)0.624 [a](#tb2fn1){ref-type="table-fn"}\
0.019 [b](#tb2fn2){ref-type="table-fn"}0.076 [a](#tb2fn1){ref-type="table-fn"}\
0.129 [b](#tb2fn2){ref-type="table-fn"}\
Creatinine, mg/dl, median (IQR)0.9 (0.7--1.1)0.86\
(0.69--1.0)0.88\
(0.7--1.0)0.969 [a](#tb2fn1){ref-type="table-fn"}\
0.934 [b](#tb2fn2){ref-type="table-fn"}1.00 (0.9--1.2)1.0\
(0.9--1.1)1.1\
(1--1.2)0.956 [a](#tb2fn1){ref-type="table-fn"}\
0.783 [b](#tb2fn2){ref-type="table-fn"}0.433 [a](#tb2fn1){ref-type="table-fn"}\
0.246 [b](#tb2fn2){ref-type="table-fn"}CRP, mg/dl\
median (IQR)8.2 (4.1--14.5)0.96\
(0.51--2.28)0.3\
(0.13--0.88)0.000 [a](#tb2fn1){ref-type="table-fn"}\
0.000 [b](#tb2fn2){ref-type="table-fn"}6.3 (2.8--13.6)5.4\
(2.8--8.9)4.6\
(2.3--6.4)0.871 [a](#tb2fn1){ref-type="table-fn"}\
0.433 [b](#tb2fn2){ref-type="table-fn"}0.003 [a](#tb2fn1){ref-type="table-fn"}\
0.000 [b](#tb2fn2){ref-type="table-fn"}\
IL-6 (pg/ml), median (IQR) [c](#tb2fn3){ref-type="table-fn"}29.4 (16--45)5 (2--9)2.3 (0--4.20.0001 [a](#tb2fn1){ref-type="table-fn"}\
0.0001 [b](#tb2fn2){ref-type="table-fn"}32.6 (25--61)29.3 (23--35.2)16.3 (12--20.5)0.189 [a](#tb2fn1){ref-type="table-fn"}\
0.087 [b](#tb2fn2){ref-type="table-fn"}0.001 [a](#tb2fn1){ref-type="table-fn"}\
0.000 [b](#tb2fn2){ref-type="table-fn"}Procalcitonin, ng/ml, median (IQR)0.6 (0.3--1.2)0.9\
(0.6--1.4)0.8 (0.6--1.8)0.625 [a](#tb2fn1){ref-type="table-fn"}\
0.567 [b](#tb2fn2){ref-type="table-fn"}0.9 (0.8--2.1)1.3\
(0.7--1.9)1.2\
(0.8--1.4)0.278 [a](#tb2fn1){ref-type="table-fn"}\
0.124 [b](#tb2fn2){ref-type="table-fn"}0.276 [a](#tb2fn1){ref-type="table-fn"}\
0.146 [b](#tb2fn2){ref-type="table-fn"}MEWS, median (IQR)1 (0--2)01\
(0--0)0\
(0--0)0.000 [a](#tb2fn1){ref-type="table-fn"}\
0.000 [b](#tb2fn2){ref-type="table-fn"}2 (1--3)1\
(1--2)1\
(0--2)0.643 [a](#tb2fn1){ref-type="table-fn"}\
0.184 [b](#tb2fn2){ref-type="table-fn"}0.004 [a](#tb2fn1){ref-type="table-fn"}\
0.012 [b](#tb2fn2){ref-type="table-fn"}ICU transfer, No (%)01 (0.88) [d](#tb2fn4){ref-type="table-fn"}0 (0)0.000 [a](#tb2fn1){ref-type="table-fn"}\
NA [b](#tb2fn2){ref-type="table-fn"}06 (7.7)14 (17.9)0.037 [a](#tb2fn1){ref-type="table-fn"}\
0.000 [b](#tb2fn2){ref-type="table-fn"}0.019 [a](#tb2fn1){ref-type="table-fn"}\
0.000 [b](#tb2fn2){ref-type="table-fn"}Discharged,\
No (%)011 (9.7)88 (77.8)0.002 [a](#tb2fn1){ref-type="table-fn"}\
0.000 [b](#tb2fn2){ref-type="table-fn"}01 (1.3)10 (12.8)1.000 [a](#tb2fn1){ref-type="table-fn"}\
0.003 [b](#tb2fn2){ref-type="table-fn"}0.039 [a](#tb2fn1){ref-type="table-fn"}\
0.000 [b](#tb2fn2){ref-type="table-fn"}Positive RT-PCR swabs at discharge, No (%) [e](#tb2fn5){ref-type="table-fn"}11 (12.5)NA4 (40)NA0.043Deaths,\
No (%)000NA02 (2.6)5 (6.4)0.477 \*\
0.069 †0.323 [a](#tb2fn1){ref-type="table-fn"}\
0.010 [b](#tb2fn2){ref-type="table-fn"}[^5][^6][^7][^8][^9][^10]

Except ageusia/anosmia, all clinical, laboratory and respiratory functions significantly improved at week 1. SpO~2~ significantly improved at week 2 (p-value: 0.0018); PaO2/FiO~2~ significantly improved at weeks 1 and 2 compared with baseline-values (p-value: 0.0016 and \<0.0001, respectively). Significant differences resulted from the comparison between the baricitinib-arm and the control-group (SpO~2~, week 1 p-value: \<0.0001; week 2 p-value: \<0.0001; PaO2/FiO2, week 1 p-value: 0.001; week 2 p-value: \<0.0001). CRP and IL-6 levels significantly decreased in the baricitinib-arm (CRP at week 1, p-value: 0.003; at week 2, p-value: \<0.0001; IL-6 at week 1, p-value: 0.001; at week 2, p-value: \<0.0001). Lymphocytes significantly increased in the baricitinib-arm, with the exception of patients with a baseline proportions-value \<5% ([Table 2](#tbl0002){ref-type="table"}).

At discharge, the proportion of patients \[positive to viral naso-pharingeal swabs was significantly lower \[12.5% (11/88)\] in the baricitinib-arm compared to the control-arm \[40% (4/10)\] (p-value: 0.043; 95%CI 0.06044--0.7737).

Seven AEs, not requiring the therapy discontinuation, were recorded in the baricitinib-arm, including transaminase increase in 4 (3.5%) patients, epistaxis due to heparin overdose in 1 patient, urinary infection in 1 patient, and oral candidiasis in 1 patient.

The results of the present observational, retrospective, longitudinal, multicenter-study in 113 consecutive-hospitalized patients with moderate pneumonia confirm the effectiveness and safety of baricitinib in patients with moderate COVID-19 pneumonia previously reported.[@bib0001] Baricitinib-therapy was started in the early phase of COVID-19 disease (median: 7-days from symptoms onset), and the early treatment and the rapid action of the drug may explain the low number of ICU admissions and deaths. The importance of early starting COVID-19 therapies is highlighted in trials of tociluzimab showing a higher efficacy to reduce ICU admission if administered during the initial phase of pneumonia.[@bib0008] ^,^ [@bib0009]

Interestingly, a significant reduction of positive naso-pharingeal swabs was observed in the baricitinib-arm at discharge, with only 12.5% positive-swabs compared to 40% in the control-group, confirming the anti-inflammatory and anti-viral effects of the baricitinib recently described in 4 patients.[@bib0010]

The short-term administration of the drug compared to the long-term treatment in rheumatoid arthritis, may probably explain the absence of serious AEs.

In conclusion, baricitinib is a promising and safe therapy in patients with moderate COVID-19 pneumonia. A randomized clinical trial is needed to confirm our findings.
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[^1]: Abbreviations and symbols: No= number;%= percentage; °C: grade Celsius; min= minute; SpO2= peripheral capillary oxygen saturation; PaO2/FiO2= ratio of arterial oxygen partial pressure to fractional inspired oxygen; SBP= systolic blood pressure; DBP= diastolic blood pressure; WBC= white blood cells; AST= serum glutamic oxaloacetic transaminase; ALT= serum alanine aminotransferase; MEWS= Modified Early Warning Score; IQR: Interquartile range.

[^2]: Baricitinib-treated arm: Baricitinib-therapy was given 4 mg/day orally combined with lopinavir/ritonavir tablets 250 mg/bid.

[^3]: Consecutive patients treated with standard of care therapy (hydroxychloroquine 200 mg/bid with lopinavir/ritonavir tablets 250 mg/bi) during the previous weeks before the first baricitnib-treated patient served as controls.

[^4]: IL-6 values were available in 58 patients of the baricitinib-treated group and in 36 controls.

[^5]: Abbreviations and symbols: No: number;%: percentage; °C: grade Celsius; min: minute; SpO2: peripheral capillary oxygen saturation; PaO2/FiO2: ratio of arterial oxygen partial pressure to fractional inspired oxygen; SBP: systolic blood pressure; DBP: diastolic blood pressure; WBC: white blood cells; AST: serum glutamic oxaloacetic transaminase; ALT: serum alanine aminotransferase; IU: international unit; MEWS: Modified Early Warning Score; IQR: Interquartile range. Statistical analysis was performed using the Wilcoxon test (for paired comparisons) or the Mann-Whitney test. P value was considered significant if \<0.05.

[^6]: Differences between the values at baseline and after 1 week.

[^7]: Differences between the values at baseline and after 2 weeks. Standard of care therapy-treated group: COVID-19 patients under standard respiratory therapy and lopinavir/ritonavir and hydroxychloroquine treatment that were admitted in the hospital the week before starting the therapy with baricitinib and lopinavir/ritonavir.

[^8]: IL-6 values were available in 58 patients of the baricitinib-treated group and in 36 controls.

[^9]: This patient required intubation 2 days after baricitinib starting; she remained 2 day in ICU and then she prosecuted the drug. She was discharged 2 days after the treatment completion with baricitinib.

[^10]: RT-PCR= real time Reverse Transcription-Polymerase Chain Reaction.
